Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Shorter Time to Treatment with Diazepam Nasal Spray Is Associated with Faster Seizure Termination: A Subpopulation Analysis

Author:Becker, Danielle   Jarrar, Randa   Stern, John   Rabinowicz, Adrian   Carrazana, Enrique   

Session Name:P9: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Mechanisms, Pharmacokinetics, and Urgent Applications  

Topic:Epilepsy/Clinical Neurophysiology (EEG)  

Program Number:P9.001  

Author Institution:University of Pennsylvania, Wilmington, DE  Phoenix Children’s Hospital, Phoenix, AZ  Geffen School of Medicine, Los Angeles, CA  Neurelis, Inc. , San Diego, CA  

Women’s Career Development Pilot Program for Neurological Trainees: Design, Implementation, and Evaluation Over Two Years

Author:Ross, Lindsay   Hassett, Catherine   Spurgeon, Elizabeth   Foldvary-Schaefer, Nancy   Mays, Maryann   

Session Name:P9: Education, Research, and Methodology: Equity, Anti-racism, and Access to Care and Medical Education  

Topic:Education, Research, and Methodology  

Program Number:P9.001  

Author Institution:Cleveland Clinic, Cleveland, OH  

Low MOG Expression in Human Thymus, Implications for Central Tolerance Mechanisms in Autoimmunity Against MOG

Author:Corbali, Osman   Parent, Audrey V.   Chitnis, Tanuja   

Session Name:P9: Autoimmune Neurology: MOGAD  

Topic:Autoimmune Neurology  

Program Number:P9.001  

Author Institution:Emory University School of Medicine , Atlanta, GA  University of California, San Francisco, San Francisco, CA  Brigham and Women's Hospital, Boston, MA  

Acute Treatment of Migraine with Zavegepant Nasal Spray Reduces the Use of Select Analgesics

Author:Kudrow, David   Mosher, Linda   Straghan, Esther   Sweeney, Samantha   Fountaine, Robert   

Session Name:P9: Headache: Advances in CGRP Inhibition 3  

Topic:Headache  

Program Number:P9.001  

Author Institution:The Los Angeles Headache Center, Los Angeles, CA  Pfizer Inc, Groton, CT  Pfizer Inc, New York, NY  

Earlier Initiation of Ublituximab Treatment Is Associated with Improved Disability Outcomes Among Treatment Naïve Participants in ULTIMATE I and II

Author:Robertson, Derrick   Hartung, Hans-Peter   Qian, Peiqing   Wray, Sibyl   Lee, Lily   Mok, Koby   Garner, Christopher   Alvarez, Enrique   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.001  

Author Institution:University of South Florida, Tampa, FL  Heinrich Heine University Medical Faculty , Dusseldorf, Germany  Swedish Medical Center, Seattle, WA  Hope Neurology, Knoxville, TN  TG Therapeutics, New York, NY  TG Therapeutics, Seal Beach, CA  University of Colorado, Aurora, CO